Plecanatide vs BYM338
Head-to-head comparison of Plecanatide (Plecanatide) and BYM338 (Bimagrumab (BYM338)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Plecanatide | BYM338 |
|---|---|---|
| Category | Gastrointestinal | Muscle & Performance |
| Full Name | Plecanatide | Bimagrumab (BYM338) |
| Molecular Weight | Approx. 1620 Da | ~148 kDa |
| Half-Life | Local intestinal action; systemic half-life not clinically meaningful | ~2-3 weeks |
| Amino Acids | 16 | N/A |
| Typical Dose | 3 mg once daily | 10-30 mg/kg IV in trials |
| Route | Oral | Intravenous |
| Purity | ≥98% | ≥98% |
| Studies Count | 350 | 140 |
| Research Status | Clinical | Clinical |
Plecanatide Benefits
- ✓improves-stool-frequency
- ✓supports-fluid-secretion
- ✓may-reduce-constipation
- ✓local-gut-action
BYM338 Benefits
- ✓increased lean mass
- ✓functional strength support
- ✓reduced muscle wasting
- ✓metabolic body-composition shift
Plecanatide Dosing
3 mg PO daily|take with or without food|avoid when dehydrated
BYM338 Dosing
IV infusion|10-30 mg/kg per study cycle|repeat every 4-12 weeks
Plecanatide Side Effects
- ⚠diarrhea
- ⚠abdominal-discomfort
- ⚠nausea
BYM338 Side Effects
- ⚠muscle cramps
- ⚠diarrhea/nausea
- ⚠infusion reactions
Research Overview
Plecanatide
Clinical trials show plecanatide improves constipation outcomes with a generally favorable tolerability profile. Like linaclotide, it acts locally in the intestinal lumen via GC-C signaling rather than systemic hormone effects.
BYM338
Clinical trials showed meaningful increases in lean mass, with mixed functional outcomes depending on population and endpoint. The antibody remains one of the best-documented receptor-blocking approaches to muscle anabolism in humans.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.